Scandidos AB (2FV)
Market Open
12 Aug, 06:04
XFRA XFRA Primary €
0. 05
-0
-8.4112%
€
5.37M Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
€ 0.05
Previous Close Want to track 2FV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
2FV trading today lower at €0.05, a decrease of -8.4112% from yesterday's close, completing a monthly increase of 16.6667% or €0.01. Over the past 12 months, 2FV stock lost -38.5965%.
2FV is not paying dividends to its shareholders.
The last earnings report, released on Mar 10, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
Scandidos AB (2FV) FAQ
What is the stock price today?
The current price is €0.05.
On which exchange is it traded?
Scandidos AB is listed on XFRA.
What is its stock symbol?
The ticker symbol is 2FV.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 5.37M.
Has Scandidos AB ever had a stock split?
No, there has never been a stock split.
Scandidos AB Profile
| Software Industry | Information Technology Sector | Mr. Carl Gustaf Piehl CEO | XFRA Exchange | SE0005768124 ISIN |
| Sweden Country | 25 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
ScandiDos AB (publ) is a pioneer in providing advanced measurement systems and software dedicated to the Quality Assurance (QA) and validation of new dynamic and modulated radiation therapy treatments in medical facilities across the globe. Established in 2001, the company is based in Uppsala, Sweden. ScandiDos AB focuses on enhancing the precision and safety of complex radiation treatments, supporting the healthcare sector's transition towards more sophisticated and tailored cancer treatment protocols.
Products and Services
ScandiDos offers a suite of products designed for the QA of innovative radiation therapy techniques, which include:
- Delta4 Discover - A state-of-the-art device that enables real-time verification of radiation therapy directly on the patient, ensuring that the treatment is delivered precisely as planned. The Delta4 Discover system is pivotal for the QA of advanced treatments, providing clinicians with immediate feedback and the possibility to adjust treatments if necessary.
- Delta4 Phantom+ - This product serves as a comprehensive solution for the pre-treatment validation of radiotherapy plans. It is utilized to verify that complex treatment plans, including those for VMAT (Volumetric Modulated Arc Therapy), RapidArc, IMRT (Intensity Modulated Radiation Therapy), and Tomotherapy, are accurately and safely implemented. The Delta4 Phantom+ allows for intricate QA procedures that ensure the intended dose is delivered to the patient, minimizing the risk to surrounding healthy tissue.
Contact Information
Address: Uppsala Science Park
Phone: 46 1 84 72 30 30
Website: https://scandidos.com
